Phase 1
N=24
Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT01999231 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Mar 2015
Primary outcome: Primary: the Cases of Adverse Events With Participant Injection of ESAT6-CFP10 — 3; 1; 0; 0 cases
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- ESAT6-CFP10 (Biological)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Primary completion
- Oct 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY the Cases of Adverse Events With Participant Injection of ESAT6-CFP10 |
3; 1; 0; 0 | — |
| SECONDARY the Number of Participants Who Appear the Induration and/or Redness 2h After Application of ESAT6-CFP10 |
0; 0; 0; 0 | — |
| SECONDARY the Number of Participants Who Appear the Induration and/or Redness 24h After Application of ESAT6-CFP10 |
0; 0; 0; 0 | — |
| SECONDARY the Number of Participants Who Appear the Induration and/or Redness 48h After Application of ESAT6-CFP10 |
0; 0; 0; 0 | — |
| SECONDARY the Number of Participants Who Appear the Induration and/or Redness 72h After Application of ESAT6-CFP10 |
0; 0; 0; 0 | — |
| SECONDARY the Number of Participants Who Appear the Induration and/or Redness 96h After Application of ESAT6-CFP10 |
0; 0; 0; 0 | — |
Summary
In the tests, small sample of clinical study about Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 ( Recombination EC Allergen） healthy adults was carried out.
24 healthy adults were included as study objects, they were randomly divided into four groups of different Recombinant Allergen EC dose (1, 5, 10μg/mL, maximum tolerated dose 20μg/mL, 6 person/dose) for single arm intradermal injection.
The main examination items :vital signs (breathing, heart rate, blood pressure, body temperature ) of each volunteer at 15min, 30min, 1h, 2h, 4h, 8h, 24h, 48h, 72h, 96h after injection, skin reactivity (redness and/or induration) diameter of injection sites,local reaction ( rash, pain, itching, and skin and mucous membranes ) ,a variety of adverse events,routine blood,routine urine, liver and kidney function, ECG and chest X-ray films before and 7 days after intradermal injection .
Preliminary evaluation of safety and tolerability of Recombinant Allergen EC applied in humans, which can provide a safe dosage range for phase II clinical study.
Eligibility Criteria
Inclusion Criteria
- Aged from 18 to 40 years old, age difference is not more than 10 years old within the same batch of healthy volunteers, the male to female ratio of cases is 1:1. Body mass index should be in the range of 20 to 27 Body Mass Index BMI: weight (Kg)/ height (M2);
- Agreed to participate in the test and sign the informed consent;
- Subjects should comply with the requirements of the clinical trial protocol and be followed;
- Subjects have no history of TB (Tuberculosis)or family history of tuberculosis;
- People have no pulmonary tuberculosis or extrapulmonary tuberculosis,respiratory symptom or systemic symptoms;
- People have no tuberculosis focus after examination by X-ray chest radiograph and sputum bacilli;
- Subjects have no acute or chronic disease, acute infectious diseases, dermatoses or skin allergy caused by various reasons;
- Physical condition: have no history of heart, liver, kidney, gastrointestinal tract, nervous system, or metabolic disturbance, etc. ECG, blood pressure, heart rate, respiratory status and lab test indexes including blood, urine, liver and kidney function, etc are all normal within 4 weeks before screening;
- No close contacts of tuberculosis;
- Subjects have not participated in other clinical drug trials or inoculated against other prophylactic and immune globulin in the nearly 3 months;
- Temperature is normal;
- Stop smoking, drinking and drinking contains caffeinated.
Exclusion Criteria
- Health people have close contacts of TB (Tuberculosis)patients, especially excreter in 3 weeks before selection;
- Suffering from any other serious disease, e.g. during cancer treatment, autoimmune disease, progressive atherosclerosis, diabetes accompanied with complications, chronic obstructive pulmonary disease (COPD) needing oxygen therapy, acute or progressive liver or kidney disease, congestive heart failure, etc.;
- People have history of allergy, convulsions, epilepsy, cerebropathy, neurological symptoms and signs;
- Patients who have impaired or abnormal immune function, e.g. patients treated with immunosuppressor or immunopotentiator, received immunoglobulin preparation or blood products or plasma extraction outside the gastrointestinal tract in 3 months, human immunodeficiency virus or related diseases;
- Acute febrile illness and infection;
- Taking part in other clinic trials;
- Subjects have participated in any other clinical drug trials in 3 months before our clinical tests;
- Allergic constitution, e.g. patients have allergic history to two or more kinds of drugs or food, or drug components;
- Substance abuse and alcoholics ;
- Pregnant or breast feeding women;
- Mental or physical disability;
- Informed leavers;
- Any other cases that may influence the test evaluation.
Data sourced from ClinicalTrials.gov (NCT01999231). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.